Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366834 · ClinicalTrials.gov registry record · Phase 3
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,840
- Enrollment target
NCT00366834 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,840 participants.
The verdict
NCT00366834, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,840 participants
- Enrollment target
Study Summary
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Interventions
- DRUG placebo
- DRUG Casopitant (GW679769) oral tablets
- DRUG Casopitant (GW679769) intravenous
- DRUG Dexamethasone intravenous
- DRUG Ondansetron oral tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,840 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366834
The ClinicalTrials.gov registry entry for NCT00366834 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT00366834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366834 about?
NCT00366834 is a clinical study titled "Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting". This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
What is the current status of trial NCT00366834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,840 participants. The study started on 2006-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00366834?
The interventions under investigation include: placebo (DRUG), Casopitant (GW679769) oral tablets (DRUG), Casopitant (GW679769) intravenous (DRUG), Dexamethasone intravenous (DRUG), Ondansetron oral tablets (DRUG).
Who is sponsoring clinical trial NCT00366834?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.